Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

Potential For Post-Tagrisso Therapy Niche

Executive Summary

The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.

You may also be interested in...



Advanced Antibodies Will Revolutionize The Future Of IO

Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.

Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout

Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.

Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology

Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel